Drug Shortage Report for NAT-QUETIAPINE
Report ID | 82236 |
Drug Identification Number | 02439174 |
Brand name | NAT-QUETIAPINE |
Common or Proper name | Quetiapine Fumarate |
Company Name | NATCO PHARMA (CANADA) INC |
Market Status | MARKETED |
Active Ingredient(s) | QUETIAPINE |
Strength(s) | 150MG |
Dosage form(s) | TABLET |
Route of administration | ORAL |
Packaging size | 100 |
ATC code | N05AH |
ATC description | ANTIPSYCHOTICS |
Reason for shortage | Requirements related to complying with good manufacturing practices. |
Anticipated start date | 2019-04-23 |
Actual start date | 2019-04-23 |
Estimated end date | |
Actual end date | 2021-10-30 |
Shortage status | Resolved |
Updated date | 2021-10-31 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 2000 ARGENTIA ROAD, PLAZA 1, SUITE 200 MISSISSAUGA, ONTARIO CANADA L5N 1P7 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v7 | 2021-10-31 | French | Compare |
v6 | 2021-10-14 | English | Compare |
v5 | 2019-06-17 | French | Compare |
v4 | 2019-06-17 | English | Compare |
v3 | 2019-04-23 | English | Compare |
v2 | 2019-04-23 | English | Compare |
v1 | 2019-04-23 | English | Compare |
Showing 1 to 7 of 7